A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of S-297995 for the Treatment of Opioid-Induced Constipation in Subjects With Non-Malignant Chronic Pain Receiving Opioid Therapy.
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Naldemedine (Primary)
- Indications Constipation
- Focus Therapeutic Use
- 19 May 2015 According to Shionogi media release, data will be presented as a late-breaker abstract at the Digestive Disease Week meeting.
- 19 May 2015 Primary endpoint has been met (Spontaneous bowel movement), as reported in Shionogi media release.
- 19 May 2015 Results published in the Shionogi media release.